- Home
- ANVS vs CTMX Comparison
ANVS vs CTMX Comparison
Compare ANVS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- CTMX
- Stock Information
- Founded
- ANVS 2008
- CTMX 2008
- Country
- ANVS United States
- CTMX United States
- Employees
- ANVS N/A
- CTMX N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- CTMX Health Care
- Exchange
- ANVS Nasdaq
- CTMX Nasdaq
- Market Cap
- ANVS 44.6M
- CTMX 444.3M
- IPO Year
- ANVS 2020
- CTMX 2015
- Fundamental
- Price
- ANVS $2.67
- CTMX $2.39
- Analyst Decision
- ANVS Strong Buy
- CTMX Strong Buy
- Analyst Count
- ANVS 4
- CTMX 2
- Target Price
- ANVS $18.00
- CTMX $5.00
- AVG Volume (30 Days)
- ANVS 433.2K
- CTMX 2.4M
- Earning Date
- ANVS 08-14-2025
- CTMX 08-07-2025
- Dividend Yield
- ANVS N/A
- CTMX N/A
- EPS Growth
- ANVS N/A
- CTMX 128.27
- EPS
- ANVS N/A
- CTMX 0.49
- Revenue
- ANVS N/A
- CTMX $147,557,000.00
- Revenue This Year
- ANVS N/A
- CTMX N/A
- Revenue Next Year
- ANVS N/A
- CTMX N/A
- P/E Ratio
- ANVS N/A
- CTMX $4.91
- Revenue Growth
- ANVS N/A
- CTMX 23.81
- 52 Week Low
- ANVS $1.11
- CTMX $0.40
- 52 Week High
- ANVS $13.91
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- ANVS 57.27
- CTMX 52.18
- Support Level
- ANVS $2.63
- CTMX $2.36
- Resistance Level
- ANVS $2.97
- CTMX $2.79
- Average True Range (ATR)
- ANVS 0.25
- CTMX 0.17
- MACD
- ANVS 0.03
- CTMX -0.02
- Stochastic Oscillator
- ANVS 82.61
- CTMX 44.25
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.